Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine microspheres
- Development stage
- Phase 1
- Lead developer
- Beijing Biote Pharmaceutical
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
N02 is an injectable formulation of bupivacaine microspheres developed by Beijing Biote Pharmaceutical for the management of postoperative pain. Bupivacaine is an amide-type local anesthetic that reversibly binds to and blocks voltage-gated sodium channels on nerve cell membranes, preventing the influx of sodium ions and the subsequent generation and conduction of nerve impulses. By utilizing a microsphere-based sustained-release delivery system, N02 is designed to provide prolonged local analgesia at the surgical site, reducing the need for systemic opioids and improving postoperative recovery. N02 is currently in Phase 1 clinical development in China.
- Other names
- Bupivacaine Microspheres for Injection注射用布比卡因微球
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on bupivacaine microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine microspheres.